Why Is Viridian Therapeutics (VRDN) Stock Down -32% Today?
Key Takeaways
- Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63
- The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event
- The magnitude of the selloff signals the market's sharp disappointment with the data relative to the high expectations set by the prior success of intravenous veligrotug in THRIVE and THRIVE-2
- The company had repeatedly guided investors toward a Q1 2026 REVEAL-1 readout as a pivotal milestone, making today's data release the most watched catalyst in the stock's recent history
- Analysts hold a consensus Buy rating with an average price target near $40.55, but sharp downward revisions are expected as Wall Street reassesses the subcutaneous elegrobart program
- Investors will now focus on the REVEAL-2 readout (expected Q2 2026), the PDUFA decision for intravenous veligrotug on June 30, 2026, and management's next strategic update
Opening Summary
Viridian Therapeutics, Inc. (VRDN) is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on developing medicines for serious and rare diseases, with its primary pipeline targeting thyroid eye disease (TED) — a debilitating autoimmune condition affecting the muscles and fatty tissues around the eyes. Shares are plunging approximately 32.00% in premarket trading on Monday, March 30, 2026, falling from a prior session close of $27.39 to approximately $18.63, as the company released topline Phase 3 REVEAL-1 data for its subcutaneous candidate elegrobart (VRDN-003) in patients with active TED. The scale of the premarket decline reflects significant investor disappointment, as the REVEAL-1 readout had been positioned as one of the most transformative catalysts in VRDN's near-term pipeline story.
REVEAL-1 Data Release: The Primary Catalyst
The steep selloff in VRDN) centers on the topline results from REVEAL-1, the company's Phase 3 pivotal trial evaluating elegrobart (VRDN-003) dosed subcutaneously every four weeks in patients with active TED. Viridian had openly telegraphed this readout for Q1 2026, and CEO Steve Mahoney stated in the company's February 25, 2026 earnings update that the company was "advancing toward reporting pivotal REVEAL-1 topline data for elegrobart next month," directly pointing to March. The market's severe negative reaction, consistent with a major clinical disappointment in biotechnology, indicates the data did not meet the bar set by the company's prior Phase 3 wins with intravenous veligrotug in THRIVE and THRIVE-2, where all primary and secondary endpoints were met with high statistical significance.
Weight of Expectations and Pipeline Risk
A key reason the selloff is so severe is the enormous weight of expectations that had been placed on the elegrobart program. Veligrotug's intravenous formulation had already demonstrated robust efficacy in both active and chronic TED, setting a high bar for the more patient-friendly subcutaneous successor. Management and analysts alike had argued that VRDN-003's shared IGF-1R binding domain with veligrotug would translate seamlessly into Phase 3 success. With those expectations now challenged, the market is rapidly repricing VRDN's long-term commercial opportunity, particularly the vision of elegrobart as a differentiated, at-home, self-administered therapy competing with Tepezza and next-generation pipeline entrants.
Analyst Sentiment and Valuation Reset
Going into today, VRDN) carried strong institutional support — Wedbush had reissued an Outperform rating with a $44 price target as recently as March 11, 2026, and RBC Capital maintained Outperform at $42 following Q4 earnings. Jefferies had also maintained a Buy rating at $45, citing REVEAL-1 as a key upside driver. That analyst consensus, which implied roughly 50%+ upside from the prior close, was built almost entirely on the assumption of positive REVEAL-1 results and a successful commercial trajectory for elegrobart. Expect significant downward revisions to price targets and potential rating changes as sell-side desks update their models in response to the data.
Market Context and Trading Activity
The broader biotech sector has faced ongoing headwinds entering the second quarter of 2026, with macro uncertainty and shifting risk appetite weighing on clinical-stage names. VRDN's premarket volume is expected to be significantly elevated relative to its average daily trading activity, consistent with a binary data event reaction. The stock had already been trending below its 50-day moving average of approximately $30.55 in recent weeks, and today's move breaks materially below the stock's 200-day moving average and its 52-week low range, a technically significant threshold that could attract further downward pressure from algorithmic and momentum-driven selling.
Trending AI Robots
For traders navigating volatile biotech sessions like today's action in VRDN, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots across thousands of tickers, spanning a wide range of strategies, timeframes, risk profiles, and traded symbols — but only the strongest performers, as measured by real-time and recent backtested metrics, are featured in the Trending section. Whether you are looking for bots optimized for short-term momentum plays, swing trading, or sector rotation strategies, the Trending AI Robots section helps narrow the field quickly. Traders looking for data-driven, AI-guided approaches to volatile market environments may find value in exploring what is currently trending.
What Comes Next for VRDN
The immediate focus for VRDN) investors now shifts to several upcoming catalysts that will shape the company's near-term trajectory. The FDA PDUFA target action date for intravenous veligrotug remains June 30, 2026, and a potential approval and commercial launch in TED could provide a meaningful offset to today's elegrobart setback. Management is also expected to address investor questions about the REVEAL-1 data on a conference call and will need to clarify the path forward for the elegrobart program — including whether there is any subgroup or secondary analysis that could support a revised development strategy. REVEAL-2, the companion Phase 3 study in chronic TED, remains on track for a Q2 2026 readout, and those results will be closely scrutinized by investors and analysts assessing whether the REVEAL-1 outcome reflects a broader program issue or a study-specific anomaly. Additionally, the company holds a strong cash position with runway into the second half of 2027, providing financial flexibility despite the pipeline setback, and the VRDN-008 program in autoimmune disease remains in Phase 1 clinical development with data expected in 2H 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
VRDN's Indicator enters downward trend
The Aroon Indicator for VRDN entered a downward trend on September 30, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 233 similar instances where the Aroon Indicator formed such a pattern. In 207 of the 233 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRDN as a result. In 64 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for VRDN turned negative on August 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
VRDN moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRDN crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VRDN's RSI Oscillator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
VRDN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.132) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (30.488) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology
Advertisement